Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.72 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412658 | 0.93 | PDE2A (0.72) | PDE2AFYNGABRA1GABRG2GABRB3 | |
| SCHEMBL4708377 | 0.90 | PDE2A (0.66) | PDE2AFYNGABRA1GABRG2GABRB3 | |
| SCHEMBL4708347 | 0.86 | PDE2A (0.68) | PDE2AFYNGABRA1GABRG2GABRB3 | |
| SCHEMBL4423105 | 0.85 | PDE2A (0.63) | PDE2AFYNGABRA1GABRG2GABRB3 | |
| SCHEMBL4709022 | 0.85 | PDE2A (0.66) | PDE2AFYNGABRA1GABRG2GABRB3 | |
| SCHEMBL29883862 | 0.84 | PDE2A (1.00) | PDE2AGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29390221 | 0.84 | PDE2A (1.00) | PDE2AGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5034638 | 0.84 | PDE2A (1.00) | PDE2AGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4708597 | 0.83 | PDE2A (0.85) | PDE2AFYNGABRA1GABRG2GABRB3 | |
| SCHEMBL4707943 | 0.83 | GABRA1 (0.56) | PDE2AGABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556055-B1 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE AND THEIR USE IN THERAPY | VIA PHARMACEUTICALS INC (US) | 2008-10-29 | — | — | EP | claimed |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | NEURO3D (FR) | 2006-06-15 | — | — | US | claimed |
| JP-2006509832-A | — | — | 2006-03-23 | — | — | JP | claimed |
| EP-1556055-A2 | USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY | NEURO3D (FR) | 2005-07-27 | — | — | EP | claimed |
| WO-2004041258-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES | NEURO3D (FR) | 2004-05-21 | — | — | WO | claimed |
| EP-1556055-B1 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE AND THEIR USE IN THERAPY | VIA PHARMACEUTICALS INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | NEURO3D (FR) | 2006-06-15 | — | — | US | disclosed |
| EP-1556055-A2 | USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY | NEURO3D (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041258-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES | NEURO3D (FR) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | PDE7A, PDE4A, PDE4B | PDE2A 5/4885FYN 2601/4885GABRA1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.